Autoimmune Pulmonary Alveolar Proteinosis
Seminars in Respiratory and Critical Care Medicine · 01.08.2026 · 47 (04) · 359-372
DOI: 10.1055/a-2737-7719 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Seminars in Respiratory and Critical Care Medicine, erschienen am 01.08.2026. Verfasst von Spyros A Papiris und 8 weiteren Autor:innen. Beteiligte Einrichtung: Athens Medical School, National and Kapodistrian University of Athens, Athens, Greece. Hauptthemen laut MEDLINE: Pulmonary Alveolar Proteinosis, Autoimmune Diseases, Granulocyte-Macrophage Colony-Stimulating Factor. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 170 Literaturangaben.
Abstract (Originalsprache)
Autoimmune pulmonary alveolar proteinosis (aPAP) is a rare disease characterized by abnormal accumulation of surfactant in alveoli. Pathogenetically, in aPAP, the presence of granulocyte macrophage-colony stimulating factor (GM-CSF) autoantibodies hinders physiological binding of GM-CSF to its receptor, disrupting terminal differentiation of alveolar macrophages and the activation GM-CSF–PU.1–PPARG1–ABCG1 axis, resulting in a primary reduction in cholesterol efflux from alveolar macrophages and a secondary reduction in surfactant clearance through macrophages from the alveolar surface. APAP is the most common, accounting for more than 90 to 95% of all patients included under the PAP term, which encompasses and classifies all forms of PAP according to etiopathogenetic mechanisms, as primary, secondary, congenital, and unclassified. APAP is worldwide distributed with an estimated prevalence fluctuating between 7.0 and 9.7 cases/million and an annual incidence of 1.65, affecting middle-aged men and women. Clinical manifestation may be gradual and insidious, mainly manifesting with progressive dyspnea, but the natural history is variable, since some patients stabilize for a long period, while others progress to respiratory failure and death; in a minority, spontaneous resolution may be observed, while some develop lung and/or systemic infections, and rarely pulmonary fibrosis. Until recently, whole lung lavage (WLL) was universally accepted as the gold-standard therapeutic modality in aPAP. However, after considerable progress in the past 25 years and the publication of several positive studies, replacing the use of inhaled-GM-CSF as the standard of care for aPAP and conceding WLL a rescue option is becoming more and more concrete. In conclusion, aPAP is the classic paradigm of a scientific disease progressing from the “bench-to-bedside,” since several discoveries made in the laboratory setting have become necessary to clarify its pathogenetic mechanisms, define diagnostic tools, and implement new therapeutic modalities, which established the disease as treatable and fully reversible, literally, moving patients from “hell to heaven.”
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Athens Medical School, National and Kapodistrian University of Athens, Athens, Greece.
- 2nd Pulmonary Medicine Department, General University Hospital "Attikon," Medical School, National and Kapodistrian University of Athens, Athens, Greece.
- Radiologia, Villa Erbosa, Gruppo San Donato, Bologna, Italy.
- School of Medicine, University College Dublin, Dublin, Ireland.
- 2nd Department of Radiology, General University Hospital "Attikon," Medical School, National and Kapodistrian University of Athens, Athens, Greece.
- 7th Pulmonary Department, Athens Chest Hospital "Sotiria," Athens, Greece.
Zitieren
APA
Papiris, S. A., Kallieri, M., Zompatori, M., Forde, S. H., Prountzos, S., Kolilekas, L., Papaioannou, A. I., Griese, M., & Manali, E. D. (2026). Autoimmune Pulmonary Alveolar Proteinosis. Seminars in Respiratory and Critical Care Medicine, 47(04), 359-372. https://doi.org/10.1055/a-2737-7719
Vancouver
Papiris SA, Kallieri M, Zompatori M, Forde SH, Prountzos S, Kolilekas L, et al. Autoimmune Pulmonary Alveolar Proteinosis. Seminars in Respiratory and Critical Care Medicine. 2026;47(04):359-372. doi:10.1055/a-2737-7719
BibTeX
@article{Papiris2026,
author = {Papiris, Spyros A and Kallieri, Maria and Zompatori, Maurizio and Forde, Sarah H and Prountzos, Spyridon and Kolilekas, Lykourgos and Papaioannou, Andriana I and Griese, Matthias and Manali, Effrosyni D},
title = {Autoimmune Pulmonary Alveolar Proteinosis},
journal = {Seminars in Respiratory and Critical Care Medicine},
year = {2026},
volume = {47},
number = {04},
pages = {359--372},
doi = {10.1055/a-2737-7719}
}
EUVIMED